Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate

M. M. Kalstad; A. Panitch; G. R. Ehteshami; Stephen Massia

Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate

M. M. Kalstad, A. Panitch, G. R. Ehteshami, Stephen Massia

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

The polysaccharide dextran, prepared as a colloid suspension in physiological saline, is routinely used as a plasma extender or substitute for emergency treatment of massive blood and fluid loss in settings where blood and blood products are not readily available. The objective of this study is to develop a dextran-peptide conjugate that selectively self-assembles onto injured tissue surfaces to form a protective colloid barrier against trauma-induced systemic inflammatory cell damage to healthy tissues. Endothelial cells were treated in vitro with a CD11b/CD18 antagonist conjugated to dextran. This agonist peptide conjugated to dextran decreased monocyte adhesion to TNF-α-activated endothelium more effectively than peptide alone. The scrambled version of the same peptide, conjugated and not, did not block monocyte adhesion in similarly activated endothelium. These studies indicate that an CD11b/CD18 antagonist dextran conjugate that is delivered introvascularly may limit organ damage following intestinal ischemia and reperfusion injury.

Original language	English (US)
Title of host publication	Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings
Pages	736-737
Number of pages	2
Volume	1
State	Published - 2002
Event	Proceedings of the 2002 IEEE Engineering in Medicine and Biology 24th Annual Conference and the 2002 Fall Meeting of the Biomedical Engineering Society (BMES / EMBS) - Houston, TX, United States Duration: Oct 23 2002 → Oct 26 2002

Other

Other	Proceedings of the 2002 IEEE Engineering in Medicine and Biology 24th Annual Conference and the 2002 Fall Meeting of the Biomedical Engineering Society (BMES / EMBS)
Country/Territory	United States
City	Houston, TX
Period	10/23/02 → 10/26/02

Keywords

Adhesion molecule
Dextran conjugate
ICAM
Immune response
Integrin
Plasma extender

ASJC Scopus subject areas

Bioengineering

Cite this

Kalstad, MM, Panitch, A, Ehteshami, GR & Massia, S 2002, Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate. in Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings. vol. 1, pp. 736-737, Proceedings of the 2002 IEEE Engineering in Medicine and Biology 24th Annual Conference and the 2002 Fall Meeting of the Biomedical Engineering Society (BMES / EMBS), Houston, TX, United States, 10/23/02.

@inproceedings{46c1a82a93d440bb98546d1a1b7083f9,

title = "Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate",

abstract = "The polysaccharide dextran, prepared as a colloid suspension in physiological saline, is routinely used as a plasma extender or substitute for emergency treatment of massive blood and fluid loss in settings where blood and blood products are not readily available. The objective of this study is to develop a dextran-peptide conjugate that selectively self-assembles onto injured tissue surfaces to form a protective colloid barrier against trauma-induced systemic inflammatory cell damage to healthy tissues. Endothelial cells were treated in vitro with a CD11b/CD18 antagonist conjugated to dextran. This agonist peptide conjugated to dextran decreased monocyte adhesion to TNF-α-activated endothelium more effectively than peptide alone. The scrambled version of the same peptide, conjugated and not, did not block monocyte adhesion in similarly activated endothelium. These studies indicate that an CD11b/CD18 antagonist dextran conjugate that is delivered introvascularly may limit organ damage following intestinal ischemia and reperfusion injury.",

keywords = "Adhesion molecule, Dextran conjugate, ICAM, Immune response, Integrin, Plasma extender",

author = "Kalstad, {M. M.} and A. Panitch and Ehteshami, {G. R.} and Stephen Massia",

year = "2002",

language = "English (US)",

volume = "1",

pages = "736--737",

booktitle = "Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings",

note = "Proceedings of the 2002 IEEE Engineering in Medicine and Biology 24th Annual Conference and the 2002 Fall Meeting of the Biomedical Engineering Society (BMES / EMBS) ; Conference date: 23-10-2002 Through 26-10-2002",

}

TY - GEN

T1 - Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate

AU - Kalstad, M. M.

AU - Panitch, A.

AU - Ehteshami, G. R.

AU - Massia, Stephen

PY - 2002

Y1 - 2002

N2 - The polysaccharide dextran, prepared as a colloid suspension in physiological saline, is routinely used as a plasma extender or substitute for emergency treatment of massive blood and fluid loss in settings where blood and blood products are not readily available. The objective of this study is to develop a dextran-peptide conjugate that selectively self-assembles onto injured tissue surfaces to form a protective colloid barrier against trauma-induced systemic inflammatory cell damage to healthy tissues. Endothelial cells were treated in vitro with a CD11b/CD18 antagonist conjugated to dextran. This agonist peptide conjugated to dextran decreased monocyte adhesion to TNF-α-activated endothelium more effectively than peptide alone. The scrambled version of the same peptide, conjugated and not, did not block monocyte adhesion in similarly activated endothelium. These studies indicate that an CD11b/CD18 antagonist dextran conjugate that is delivered introvascularly may limit organ damage following intestinal ischemia and reperfusion injury.

AB - The polysaccharide dextran, prepared as a colloid suspension in physiological saline, is routinely used as a plasma extender or substitute for emergency treatment of massive blood and fluid loss in settings where blood and blood products are not readily available. The objective of this study is to develop a dextran-peptide conjugate that selectively self-assembles onto injured tissue surfaces to form a protective colloid barrier against trauma-induced systemic inflammatory cell damage to healthy tissues. Endothelial cells were treated in vitro with a CD11b/CD18 antagonist conjugated to dextran. This agonist peptide conjugated to dextran decreased monocyte adhesion to TNF-α-activated endothelium more effectively than peptide alone. The scrambled version of the same peptide, conjugated and not, did not block monocyte adhesion in similarly activated endothelium. These studies indicate that an CD11b/CD18 antagonist dextran conjugate that is delivered introvascularly may limit organ damage following intestinal ischemia and reperfusion injury.

KW - Adhesion molecule

KW - Dextran conjugate

KW - ICAM

KW - Immune response

KW - Integrin

KW - Plasma extender

UR - http://www.scopus.com/inward/record.url?scp=0036908086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036908086&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:0036908086

VL - 1

SP - 736

EP - 737

BT - Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings

T2 - Proceedings of the 2002 IEEE Engineering in Medicine and Biology 24th Annual Conference and the 2002 Fall Meeting of the Biomedical Engineering Society (BMES / EMBS)

Y2 - 23 October 2002 through 26 October 2002

ER -

Inhibition of ICAM-mediated monocyte adhesion with a bioresponsive dextran-based conjugate

Abstract

Other

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this